26/02/2026
Why Entheogens Don’t Work for Everyone — And What Really Matters
People often talk about entheogens as if the molecule itself is the main healing agent. But recent meta-research on psilocybin-assisted therapy shows something different.
Yes, the substance can enhance outcomes — but its effectiveness depends far more on how the therapeutic process around it is designed and delivered.
Researchers reviewed seven randomized clinical studies with over 500 participants. They didn’t just ask “does psilocybin help?” — they examined what makes the effect stronger or weaker:
* whether the dose was personalized or one-size-fits-all
* how much time was spent on preparation
* how long the session lasted
* how deeply integration was practiced
* whether support was rigidly manualized or adaptively therapeutic
The overall finding was familiar: psilocybin-assisted therapy has a clear antidepressant effect.
But the real insight lies in when that effect is strongest.
What Makes a Difference?
The biggest improvements appeared in studies where:
-doses were tailored to the individual, not standardized
-preparation was thorough, not brief
-sessions were spacious, without rushing the process
-integration was given real depth, not just a formality
-therapeutic support was adaptive and relational, not rigidly prescriptive
This isn’t decoration — this is what drives the result.
The Core Message
Entheogens do not “heal depression” by themselves.
The molecule isn’t the active agent in isolation — the context is.
Psilocybin amplifies:
-the quality of the therapeutic relationship
-the capacity for meaning-making
-the depth of emotional engagement
-the integration of experience into everyday life
Without those elements, the effect is weaker, shorter, or unstable.
A Subtle but Crucial point.
